On July 21, 2022, Dr. Kevin D'Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc. delivered his notice of resignation. The Company and Dr. D'Amour have not yet determined the effective date of Dr. D'Amour's resignation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.855 USD | +8.48% | +3.64% | +3.34% |
03-15 | North American Morning Briefing : Inflation -2- | DJ |
03-14 | Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+3.34% | 10.04M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Chief Scientific Officer